Trevi Therapeutics (TRVI) Tops Q2 EPS by 1c

Trevi Therapeutics (NASDAQ: TRVI) reported Q2 EPS of ($0.09), $0.01 better than the analyst estimate of ($0.10).

For earnings history and earnings-related data on Trevi Therapeutics (TRVI) click here.

You May Also Be Interested In

• Goldman Sachs (GS) Reiterated at Market Perform by Citizens on Constructive Backdrop
• Jefferies Financial Group (JEF) Misses Q2 EPS by 22c
• NRC Health (NRC) Reiterated at Market Outperform by Citizens Ahead of Annual Forum